Nanomedicine News

RSS

Arcturus, Janssen Collaborate to Commercialize RNA-Based Drugs Using Nanoparticle Delivery Platform

Arcturus Therapeutics, Inc., a leading RNA medicines company, announced today that it has entered into a research collaboration and worldwide license agreement with Janssen Pharmaceuticals, Inc. (Janssen). Under the agreement, facilitated by J&J Innovation, the parties will work together to develop and commercialize RNA-based drug products for the treatment of specified diseases using Arcturus' UNA Oligomer™ chemistry and LUNAR™ nanoparticle delivery platform.

12 Jun 2015

Merrimack Expands Phase 1 Study of Iron Oxide Nanoparticle Marker for nal-IRI Tumor Response Prediction

Merrimack Pharmaceuticals, Inc. today announced the initiation of clinical imaging assessing the use of a potential marker for delivery of MM-398 (irinotecan liposome injection), also known as "nal-IRI," to metastatic breast cancer.

12 Jun 2015

Battery-Less Implantable CardioMEMS Sensor Device for Advanced Heart Failure Patients

Cardiologists at The Mount Sinai Hospital have begun implanting tiny, state-of-the-art microchip sensors in patients with advanced heart failure to better monitor symptoms and reduce their chances of returning to the hospital.

12 Jun 2015

Nanoparticles Specifically Target Tough Cancer Stem Cells

Many cancer patients survive treatment only to have a recurrence within a few years. Recurrences and tumor spreading are likely due to cancer stem cells that can be tough to kill with conventional cancer drugs.

11 Jun 2015

Immune Pharmaceuticals Successfully Incorporates Cyclosporine A into Biodegradable Nano-Capsules

Immune Pharmaceuticals Inc. announced today that it has entered into a binding Memorandum of Understanding with Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem regarding the worldwide exclusive licensing and development of a topical, biodegradable, nano-capsule formulation of cyclosporine A.

11 Jun 2015

Positive Intermediate Results from Nanobiotix’s NBTXR3 Phase I/II Clinical Trial in Head and Neck Cancer

NANOBIOTIX (Paris:NANO) (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces positive preliminary safety results for its lead NanoXray product NBTXR3, in its head and neck cancer Phase I/II clinical trial.

10 Jun 2015

Nanoparticles Arrest Destruction of Beta Cells and Avoid Diabetes Development

Two years ago, the Immunology of Diabetes Research Group at the Germans Trias Research Institute (at Universitat Autònoma de Barcelona - Campus of International Excellence Sphere) reported a new experimental immunotherapy that prevented the onset of Type 1 Diabetes in mice predisposed to the disease.

10 Jun 2015

Injectable Nano-Scale Electronic Scaffolds to Monitor Neural Activity

It's a notion that might be pulled from the pages of science-fiction novel - electronic devices that can be injected directly into the brain, or other body parts, and treat everything from neurodegenerative disorders to paralysis.

9 Jun 2015

Innovative Hand-Held Tool and App to Monitor for Signs of Skin Cancer Unveiled at World Dermatology Conference

Simon Fraser University PhD alumna Maryam Sadeghi is unveiling MoleScope™, an innovative hand-held tool that uses a smartphone to monitor skin for signs of cancer, at the World Congress of Dermatology conference in Vancouver June 9-13.

9 Jun 2015

NCI Nanotechnology Characterization Laboratory Selects Rexahn’s RX-21101 for Preclinical Characterization Program

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that its drug candidate RX-21101 was selected by the National Cancer Institute's (NCI) Nanotechnology Characterization Laboratory (NCL) for its preclinical characterization program to help facilitate the advance of RX-21101 towards human clinical trials.

9 Jun 2015

Nanomedicine News

Arcturus, Janssen Collaborate to Commercialize RNA-Based Drugs Using Nanoparticle Delivery Platform

Merrimack Expands Phase 1 Study of Iron Oxide Nanoparticle Marker for nal-IRI Tumor Response Prediction

Battery-Less Implantable CardioMEMS Sensor Device for Advanced Heart Failure Patients

Nanoparticles Specifically Target Tough Cancer Stem Cells

Immune Pharmaceuticals Successfully Incorporates Cyclosporine A into Biodegradable Nano-Capsules

Positive Intermediate Results from Nanobiotix’s NBTXR3 Phase I/II Clinical Trial in Head and Neck Cancer

Nanoparticles Arrest Destruction of Beta Cells and Avoid Diabetes Development

Injectable Nano-Scale Electronic Scaffolds to Monitor Neural Activity

Innovative Hand-Held Tool and App to Monitor for Signs of Skin Cancer Unveiled at World Dermatology Conference

NCI Nanotechnology Characterization Laboratory Selects Rexahn’s RX-21101 for Preclinical Characterization Program

Enhanced Antibacterial Polylactic Acid-Curcumin Nanofibers for Wound Dressings

Gold Nanoparticles to Restore Vision in Retinal Disorders

Levidian and Zentek Seek to Establish Graphene-Integrated Filter Manufacturing Facility in the Middle East to Advance Cleaner, Safer Air

Scalable Method for Porous Graphene Membranes for CO2 Capture

Biochar-Modified Titanium Dioxide Nanocomposites for Enhanced Water Treatment

Overcoming Nanogold Production Challenges

Electrospinning and the Future of Nanotechnology

How Electrospinning is Shaping the Future of Nanotechnology

Sponsored Content

Utilizing Back-Gate Voltage Biases for 2D Materials

Resistivity Metrology for Sputtered ITO Thin Films

How Plasma Cleaning Technology Tackles Hydrocarbon Contamination

Optimizing EV Lubricants with Electrified Tribotesting